Key Insights

Highlights

Success Rate

63% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

37.5%

3 terminated out of 8 trials

Success Rate

62.5%

-24.0% vs benchmark

Late-Stage Pipeline

75%

6 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results63% success

Data Visualizations

Phase Distribution

8Total
P 2 (2)
P 3 (6)

Trial Status

Completed5
Terminated3

Trial Success Rate

62.5%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (8)

Research Network

Activity Timeline